Experimental drug LY4268989 put to the test: does meal timing matter?
NCT ID NCT07707375
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This early-phase study tests an experimental oral drug called LY4268989 (MORF-057) in 50 healthy adults. Researchers want to see if two different tablet forms are processed similarly by the body, and how meals affect that process. Participants will stay at a research unit for 18 overnight visits over about 9 weeks, with blood tests to track the drug's levels and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called LY4268989 (MORF-057)
- What this could lead to
- If successful, this study could help determine the best tablet form and dosing conditions for future trials of LY4268989.
- What could go wrong
- This is an early-phase, small study in healthy volunteers, so results may not predict effects in patients. The drug may not advance to later testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test